AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 19 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Combining the angiogenesis inhibitor angiostatin and immunogene
therapy with the T-cell costimulator B7.1 not only reduces solid lymphomas, but it also elicits antitumor immunity.
Researchers in New Zealand have used a combination of angiostatin and B7.1 gene therapies to stimulate immune system response against EL-4 lymphomas in mice, suggesting the combination of these two therapies would be an effective tumor vaccine.
According to X.Y. Sun, University of Auckland, New Zealand, angiostatin gene therapy alone generated a weak antitumor response with some antiangiogenic activity in mice implanted with EL-4 lymphomas.
"In contrast, when angiostatin gene therapy was preceded by in situ gene transfer of the T-cell costimulator B7.1, large (0.4 cm in diameter) tumors were rapidly and completely eradicated," Sun and coworkers said, pointing out that neither gene therapy was as effective when used as monotherapy.
In addition, mice challenged with systemic administration of EL-4 cells after receiving combination gene therapy mounted a significant attack against those cells, combating EL-4 cell entrenchment and growth. "Gene transfer of angiostatin expression plasmids led to overexpression of angiostatin in tumors, increased apoptosis of tumor cells, and decreased density of tumor blood vessels, which may have allowed ...
Source: HighBeam Research, Immunogene Therapy Augments Angiostatin In Murine Model Of...